 |
|
All Releases
 |
OXiGENE Announces $7.5 Million Financing
Mar 11, 2010
|
10.8 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Mar 11, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,5...
|
|
OXiGENE Reports Fourth Quarter and Year-End 2009 Results
Feb 25, 2010
|
21.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 25, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and year ending December 31, 2009. The Company also provided an upda...
|
|
OXiGENE Announces Fourth Quarter and Fiscal 2009 Earnings Conference Call and Webcast
Feb 19, 2010
|
9.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 19, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report fourth quarter and fiscal year-end 2009 results, along with guidance for 2010, on Thursday, Februar...
|
|
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
Feb 11, 2010
|
11.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 11, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today a restructuring plan designed to focus resources on the company's highest-value clinical assets...
|
|
OXiGENE Announces Results of Stockholder Vote on Proposed Merger With VaxGen
Feb 4, 2010
|
9.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 4, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that at the special meeting of stockholders of OXiGENE held yesterday, the issuance of shares of...
|
|
OXiGENE Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at ASH Conference
Dec 7, 2009
|
13.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 7, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced the presentation of data from preclinical studies carried out by Christopher R. Cogle, M.D., Ass...
|
|
OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference
Nov 17, 2009
|
13.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 17, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a ...
|
|
OXiGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings
Nov 12, 2009
|
11.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 12, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from preclinical studies of its vascular disrupting agent (VDA) drug candidate OXi450...
|
|
OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences
Nov 10, 2009
|
8.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 10, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that OXiGENE Management will present a corporate overview and update at the Merriman Curhan For...
|
|
OXiGENE Reports Third Quarter 2009 Financial Results
Nov 9, 2009
|
18.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 9, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and nine months ended September 30, 2009 and presented an update on r...
|
|
OXiGENE Announces Third Quarter 2009 Earnings Conference Call and Webcast
Nov 3, 2009
|
9.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report third quarter 2009 results on Monday, November 9th, 2009. A conference call and webcast hosted by OX...
|
|
OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger
Oct 15, 2009
|
20.4 KB |
|
| |
Oct 15, 2009 (GlobeNewswire via COMTEX News Network) --
Acquisition to Add Approximately $33 Million in Cash
to OXiGENE's Balance Sheet
Conference Call Today at 9:00 AM Eastern
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a...
|
|
OXiGENE Announces Data Presentation At 2009 AACR-EORTC-NCI Conference
Oct 12, 2009
|
10.3 KB |
|
| |
WALTHAM, Mass., Oct 12, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that interim data from its randomized, controlled, Phase 2 study of ZYBRESTAT(TM) in combination with Avastin(R) ...
|
|
Oxigene Announces Management Changes
Oct 8, 2009
|
8.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 8, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that its Chief Executive Officer, John A. Kollins, has resigned from his position with the Compa...
|
|
OXiGENE Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position
Jul 30, 2009
|
19.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jul 30, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended June 30, 2009 and presented an update on recent clinical and c...
|
|
OXiGENE Announces Second Quarter 2009 Earnings Conference Call and Webcast
Jul 24, 2009
|
9.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jul 24, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report second quarter 2009 results on Thursday, July 30, 2009. A conference call and webcast hosted by OXi...
|
|
OXiGENE Announces Closing of Registered Direct Offering
Jul 21, 2009
|
10.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jul 21, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has closed a registered direct offering of 6,250,000 units of its common stock and warra...
|
|
OXiGENE to Raise $10 Million in Registered Direct Offering
Jul 15, 2009
|
10.6 KB |
|
| |
WALTHAM, Mass., Jul 15, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it will raise approximately $10 million in gross proceeds, before deducting placement agent fees and oth...
|
|
OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology
Jul 6, 2009
|
15.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jul 6, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the Company exercised its option to acquire all of the equity of Symphony ViDA, Inc. in exchange f...
|
|
OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology
Jun 25, 2009
|
12.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Jun 25, 2009 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the Company has initiated a Phase 2 study of its vascular disrupting agent (VDA) drug candidate ZYBRESTAT for ophthalmology in p...
|
|
|
= add release to Briefcase |
|
 |
|
4:00 PM ET - 03/12/10 |
|
$1.23
( 0.01)
|
Volume | 137,600 |
Day High | 1.25 |
Day Low | 1.20 |
52-week High | 2.78 |
52-week Low | 0.62 |
» more |
|
|
|
|
 |
|
 |
|
Shareholder Briefcase
Download Library
RSS News Feeds
| |
|
|
|
|
